{"id":9971,"date":"2019-03-14T11:05:02","date_gmt":"2019-03-14T10:05:02","guid":{"rendered":"https:\/\/udic.es\/?p=9971"},"modified":"2019-03-14T11:05:02","modified_gmt":"2019-03-14T10:05:02","slug":"anti-amyloid-therapy-in-initial-alzheimers-continues","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/","title":{"rendered":"Anti-amyloid therapy in initial Alzheimer&#8217;s continues."},"content":{"rendered":"<p class=\"p1\"><span class=\"s1\">Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer&#8217;s, which was positive. We have been selected to develop the phase III trial with this Eisai drug.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\"> <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer&#8217;s, which was positive. We have been selected to develop the phase III trial with this Eisai drug.<\/p>\n","protected":false},"author":2,"featured_media":9967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[129,1],"tags":[],"class_list":["post-9971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-2","category-uncategorised"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Anti-amyloid therapy in initial Alzheimer&#039;s continues. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer&#039;s, which was positive. We have been selected to develop\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti-amyloid therapy in initial Alzheimer&#039;s continues. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer&#039;s, which was positive. We have been selected to develop\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-14T10:05:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1181\" \/>\n\t<meta property=\"og:image:height\" content=\"591\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tito Surribas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tito Surribas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\"},\"author\":{\"name\":\"Tito Surribas\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\"},\"headline\":\"Anti-amyloid therapy in initial Alzheimer&#8217;s continues.\",\"datePublished\":\"2019-03-14T10:05:02+00:00\",\"dateModified\":\"2019-03-14T10:05:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\"},\"wordCount\":38,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg\",\"articleSection\":[\"Alzeimer\",\"Uncategorised\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\",\"url\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\",\"name\":\"Anti-amyloid therapy in initial Alzheimer's continues. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg\",\"datePublished\":\"2019-03-14T10:05:02+00:00\",\"dateModified\":\"2019-03-14T10:05:02+00:00\",\"description\":\"Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer's, which was positive. We have been selected to develop\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg\",\"width\":1181,\"height\":591,\"caption\":\"Blogudic1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti-amyloid therapy in initial Alzheimer&#8217;s continues.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\",\"name\":\"Tito Surribas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"caption\":\"Tito Surribas\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti-amyloid therapy in initial Alzheimer's continues. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer's, which was positive. We have been selected to develop","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/","og_locale":"en_US","og_type":"article","og_title":"Anti-amyloid therapy in initial Alzheimer's continues. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer's, which was positive. We have been selected to develop","og_url":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2019-03-14T10:05:02+00:00","og_image":[{"width":1181,"height":591,"url":"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg","type":"image\/jpeg"}],"author":"Tito Surribas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tito Surribas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/"},"author":{"name":"Tito Surribas","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e"},"headline":"Anti-amyloid therapy in initial Alzheimer&#8217;s continues.","datePublished":"2019-03-14T10:05:02+00:00","dateModified":"2019-03-14T10:05:02+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/"},"wordCount":38,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg","articleSection":["Alzeimer","Uncategorised"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/","url":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/","name":"Anti-amyloid therapy in initial Alzheimer's continues. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg","datePublished":"2019-03-14T10:05:02+00:00","dateModified":"2019-03-14T10:05:02+00:00","description":"Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer's, which was positive. We have been selected to develop","breadcrumb":{"@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2019\/03\/Blogudic1.jpg","width":1181,"height":591,"caption":"Blogudic1"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/anti-amyloid-therapy-in-initial-alzheimers-continues\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"Anti-amyloid therapy in initial Alzheimer&#8217;s continues."}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e","name":"Tito Surribas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","caption":"Tito Surribas"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/9971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=9971"}],"version-history":[{"count":1,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/9971\/revisions"}],"predecessor-version":[{"id":9972,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/9971\/revisions\/9972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9967"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=9971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=9971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=9971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}